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Atopic dermatitis (AD) is a common chronic inflamma-
tory skin disease. To date, few studies have examined 
the risk of cancer in adults with AD. However, the most 
consistent associations have been observed for skin 
cancers and lymphomas (1, 2). Potential explanatory 
factors for altered risk in AD include: (i) the use of im-
munosuppressant therapies; (ii) exposure to ultraviolet 
(UV) irradiation; and (iii) AD-related pathomechanistic 
factors, including impaired cell-mediated immunity. 
Furthermore, a compromised epithelial barrier function 
facilitating transcutaneous penetration of carcinogenic 
agents and viruses, including human papilloma virus 
(HPV), could influence the cancer risk. The aim of the 
present cross-sectional study was to investigate the oc-
currence of selected cancers among adult Danish patients 
with AD (both in- and outpatient) compared with general 
population controls. 
MATERIALS AND METHODS
This cross-sectional study was based on data from Danish admi-
nistrative registries, which contain nationwide information on 
social and healthcare-related data, such as morbidity, medication 
use, hospitalizations, and personal income. A detailed descrip-
tion of the data source and methodology of this study is given in 
Appendix S11. 
RESULTS
A total of 8,112 adult patients with a diagnosis of AD 
between 1 January 1997 and 31 December 2012, were 
included and matched based on age and sex with 40,560 
control subjects. Baseline characteristics of the study 
populations are shown in Table SI1. A significant asso-
ciation was found between AD and non-melanoma skin 
cancer (NMSC) compared with controls (2.0% and 0.8%; 
adjusted odds ratios (aOR) 2.07; 95% confidence inter-
val (95% CI) 1.67–2.55) (Table I). Similar associations 
were found for cervical cancer, which occurred in 0.6% 
and 0.3% of patients with and without AD, respectively 
(aOR 1.77; 95% CI 1.10–2.84), although the p-value 
did not reach Bonferroni corrected level of significance 
which  was set at < 0.003. Further adjustment for a proxy 
variable for smoking did not significantly change the esti-
mates (aOR 1.76; 95% CI 1.09–2.83). The prevalence of 
lymphoma was 1.2% and 0.5%, respectively (aOR 1.86; 
95% CI 1.43–2.40). Similarly, pancreatic cancer had a 
higher prevalence in patients with AD (0.3%) compared 
with controls (0.1%) (aOR 2.91; 95% CI 1.50–5.66). The 
model was further adjusted for alcohol abuse and a proxy 
variable for smoking, and the estimates were virtually 
unchanged (aOR 2.85; 95% CI 1.46–5.56). No significant 
associations were found between AD and malignant me-
lanoma (MM), or between AD and hepatic, oesophageal, 
thyroid, lung, colorectal, kidney, lower urinary tract, 
breast, ovarian, endometrial, or prostate cancer. 
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n (%) OR 95% CI p-value
Adjusted 
OR* 95% CI p-value
Any
  Pancreatic cancer 41 (0.1) 20 (0.3) 2.44 1.43–4.17 0.0011 2.91 1.50–5.66 0.0016
  Hepatic cancer 25 (0.1) 5 (0.1) 1.00 0.38–2.61 1.0000 1.12 0.35–3.52 0.8513
  Oesophageal cancer 33 (0.1) 9 (0.1) 1.36 0.65–2.85 0.4093 1.30 0.57–2.95 0.5316
  Thyroid cancer 33 (0.1) 7 (0.1) 1.06 0.47–2.40 0.8875 1.25 0.46–3.40 0.6603
  Lung cancer 236 (0.6) 68 (0.8) 1.44 1.10–1.89 0.0078 1.27 0.95–1.71 0.1080
  Colorectal cancer 285 (0.7) 78 (1.0) 1.37 1.07–1.76 0.0137 1.30 0.98–1.72 0.0675
  Kidney cancer 40 (0.1) 10 (0.1) 1.25 0.63–2.50 0.5277 1.10 0.52–2.31 0.8032
  Lower urinary tract cancer 128 (0.3) 31 (0.4) 1.21 0.81–1.80 0.3382 1.20 0.77–1.88 0.4187
  Melanoma 201 (0.5) 55 (0.7) 1.37 1.02–1.85 0.0389 1.35 0.97–1.88 0.0791
  Non-melanoma skin cancer 334 (0.8) 158 (2.0) 2.39 1.98–2.90 < 0.0001 2.07 1.67–2.55 < 0.0001
  Lymphoma 215 (0.5) 100 (1.2) 2.34 1.85–2.97 < 0.0001 1.86 1.43–2.40 < 0.0001
Women only
  Breast cancer 501 (2.0) 120 (2.4) 1.20 0.98–1.47 0.073 1.11 0.89–1.39 0.3493
  Ovarian cancer 89 (0.4) 20 (0.4) 1.12 0.69–1.83 0.6371 1.12 0.64–1.96 0.6862
  Endometrial cancer 62 (0.3) 15 (0.3) 1.21 0.69–2.13 0.5077 1.12 0.61–2.07 0.7084
  Cervical cancer 85 (0.3) 30 (0.6) 1.77 1.17–2.69 0.0074 1.77 1.10–2.84 0.0176
Men only
  Prostate cancer 215 (1.4) 44 (1.4) 1.02 0.74–1.42 0.8887 0.95 0.65–1.39 0.795
Odds ratio (ORs) were estimated using univariate and multivariate logistic regression. *Adjusted for age, sex, socioeconomic status, and number of dermatology visits.



























































The strongest association observed in our cohort was 
between AD and NMSC, which has also been shown in 
previous studies, although some have failed to identify 
this association (3, 4). Patients with AD appear to have 
SCCs localized to anatomical sites that are normally 
covered by clothes, and hence not exposed to the sun, 
suggesting that UV phototherapy could contribute to 
the risk of NMSC in these patients (4). AD-associated 
epidermal deficiency of filaggrin and its metabolite 
trans-urocanic acid may further facilitate penetration of 
UVB photons and, ultimately, the risk of DNA damage 
and skin malignancies (5). Furthermore, systemic anti-
inflammatory agents have been associated with an in-
creased risk of NMSC (6, 7). We observed no significant 
association between AD and MM, which is in line with 
most previous studies (2, 4, 8).
Adults with hospital-diagnosed AD had a higher pre-
valence of cervical cancer, although the estimates did not 
reach the Bonferroni corrected criteria for significant p-
values. A recent US case-control study reported that AD 
was more common in HPV-positive cases compared with 
HPV-negative controls (9) and loss-of-function filaggrin 
gene (FLG) mutations have been associated with incident 
HPV-related cancers and pre-cancers, suggesting that 
HPV survival or invasion could indeed be facilitated in 
individuals with filaggrin deficiency (10). Furthermore, 
smoking has been associated with both cervical cancer 
and AD, and could also be a causal link between these 
2 diseases (11). 
The increased prevalence and risk of lymphoma in 
our study is in line with a systematic review and meta-
analysis, which found a relative risk of lymphoma of 1.43 
(95% CI 1.12–1.81) in patients with AD (1). Findings 
from that same study also suggested that severity of AD 
was a significant risk factor for lymphoma (1). While 
some, but not all, data suggest that AD-associated syste-
mic and topical immunosuppressive drugs may affect the 
risk of lymphoma in patients with AD, this topic remains 
controversial (1). It is important to remember that AD and 
lymphoma may be subject to diagnostic overlap in se-
lected cases, as severe AD and erythrodermic cutaneous 
T-cell lymphoma may have similar manifestations (12). 
Finally, we found a significant association between 
AD and pancreatic cancer, and while other studies have 
reported similar results, the existing literature is scarce 
(2, 13). An increased prevalence of smoking and alcohol 
abuse in patients with AD, especially those with severe 
disease, may contribute to the risk of pancreatic cancer. 
Yet, sensitivity analyses with additional adjustment for 
markers of alcohol abuse and smoking did not yield 
significant changes compared with our primary analyses; 
thus, while smoking and alcohol abuse could partially 
explain the observed association, it is unlikely that our 
findings are explained solely by these lifestyle factors. 
Certain limitations and strengths apply to the present 
study. We were only able to identify patients with a 
hospital (inpatient and ambulatory) diagnosis of AD; 
who are likely to have more severe AD disease courses 
than patients treated by general and private practitioners. 
Due to the disease severity, these patients are expected 
to receive immunosuppressive treatment, which could 
influence the risk of several malignancies. Furthermore, 
they often undergo more thorough examination; howe-
ver, we adjusted for the number of dermatology visits to 
reduce surveillance bias. While we adjusted for age, sex, 
and number of dermatology visits in our analyses, we did 
not have information on lifestyle factors, such as diet, 
sun exposure, level of physical activity, sexual activity, 
occupation, and family history of cancer. 
In our cohort, Danish adults with AD have a hig-
her prevalence of NMSC, lymphoma, and pancreatic 
cancer compared with the general population. While 
these findings may, to some extent, be explained by 
altered immune responses, pharmacotherapy or certain 
lifestyle factors in adults with AD, causality remains to 
be established. 
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